

Brands. Generics.
Biosimilars.

Teva Canada: Committed to Canadians 🍁

At Teva Canada, we are committed to providing brands, generics and biosimilars for Canadian patients and healthcare professionals (physicians and pharmacists). See the many oncology products that we have to offer!¹⁻⁷



TEVA CANADA'S COMMITMENT TO ONCOLOGY

When it comes to brands, generics and biosimilars, Teva Canada is a key partner.^{1,3-7}



Brands^{4*}



Generics^{5,8*}

- Anastrozole
- Bicalutamide
- Bortezomib
- Cisplatin
- Dasatinib^{†‡}
- Doxorubicin HCL
- Epirubicin HCL
- Erlotinib[‡]
- Etoposide
- Everolimus^{†‡}
- Exemestane
- Fludarabine phosphate
- Fulvestrant[‡]
- Imatinib[‡]
- Letrozole
- Leucovorin calcium
- Oxaliplatin
- Sunitinib^{†‡}
- Taxomifen citrate
- Temozolomide[‡]
- Vinblastine sulfate
- Vincristine sulfate

Biosimilars^{3,4,6,7*}



At Teva Canada, we are committed to research in oncology and helping Canadians.⁹

* These lists are subject to change at any time.

† Offer patient support programs.

‡ Offer co-pay cards.

At Teva Canada, we see the value in the caregivers who offer their time, love and strength to patients. That's why we are proud to provide caregivers with resources and support.¹⁰



References: **1.** Teva Canada. "About our company." Available at: <https://www.tevacanada.com/en/about-teva/>. Accessed June 8, 2026. **2.** Teva Canada. "About Teva Canada." Available at: <https://www.tevacanada.com/en/canada/about-teva/company-profile/>. Accessed June 8, 2026. **3.** PrTRUXIMA® Product Monograph. Teva Canada Limited. April 27, 2026. **4.** Teva Canada. "Our Specialty and Biosimilar Products." Available at: <https://www.tevacanada.com/en/canada/our-products/biosimilar-medicines/specialty-biosimilar-products/>. Accessed June 8, 2026. **5.** Data on file. Letter of attestation for Teva Canada's generics in oncology. Teva Canada. June 10, 2026. **6.** Data on file. First to market rituximab biosimilar. Teva Canada. May 31, 2019. **7.** Jeong SA et al. Mechanism of action of the trastuzumab biosimilar CT-P6. *Expert Opin Biol Ther.* 2018;13:1-11. doi: 10.1080/14712598.2019.1554052. [Epub ahead of print] **8.** PrTeva-Sunitinib Product Monograph. Teva Canada Limited. March 24, 2022. **9.** Teva Canada. "Specialty products innovation." Available at: <https://www.tevacanada.com/en/our-products/specialty-medicines/specialty-products-innovation/>. Accessed June 8, 2026. **10.** Teva Canada. "Caregivers bring joy to their loved ones - we bring help to caregivers." Available at: <https://www.tevacanada.com/en/canada/support-for-caregivers/>. Accessed June 8, 2026.

TREANDA is a registered trademark of Cephalon, Inc., an affiliate of Teva Canada Innovation G.P. – S.E.N.C and is used under licence.

PrTRUXIMA® is a registered trademark of Celltrion Inc.

PrHERZUMA® is a trademark of Celltrion Inc.

© 2026 Teva Canada Innovation G.P. – S.E.N.C. Montreal, Quebec, H2Z 1S8

BIO-CA-00159E

07/2027

